Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

Share:
Related ABT
Stocks Hitting 52-Week Highs
Earnings Scheduled For July 22, 2015
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).

Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”

Abbott Laboratories closed on Friday at $65.53.

Latest Ratings for ABT

DateFirmActionFromTo
Jul 2015BarclaysMaintainsEqual-weight
Jul 2015BMO CapitalMaintainsOutperform
Jul 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Get Benzinga's Newsletters